Compare SSTI & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTI | RPTX |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.0M | 92.4M |
| IPO Year | 2017 | 2020 |
| Metric | SSTI | RPTX |
|---|---|---|
| Price | $7.79 | $2.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $15.80 | $3.00 |
| AVG Volume (30 Days) | 180.2K | ★ 1.5M |
| Earning Date | 02-24-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $102,749,000.00 | $11,870,000.00 |
| Revenue This Year | $3.98 | N/A |
| Revenue Next Year | $9.86 | $3,233.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.78 | $0.89 |
| 52 Week High | $19.43 | $2.66 |
| Indicator | SSTI | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 65.65 |
| Support Level | $7.94 | $2.52 |
| Resistance Level | $8.83 | $2.61 |
| Average True Range (ATR) | 0.53 | 0.04 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 14.94 | 29.63 |
SoundThinking Inc is a public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership. Its flagship SafetySmart platform includes ShotSpotter, the acoustic gunshot detection system, CrimeTracer, the foremost law enforcement search engine, CaseBuilder, a one-stop investigation management system, and ResourceRouter, software that directs patrol and community anti-violence resources to help maximize their impact.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.